French and US-based biopharmaceutical firm, ERYTECH Pharma S.A., is dedicated to advancing the field of red blood cell-based therapeutics for cancer treatment and orphan diseases. The company's lead asset, eryaspase, has reached Phase 3 clinical development in its efforts to treat second-line pancreatic cancer. In addition, eryaspase is currently in its Phase 2 stage for treating triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. ERYTECH Pharma S.A. also plans to develop erymethionase, a preclinical product that utilizes methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. Founded in 2004 and headquartered in Lyon, France, the company is positioned to make significant strides in cancer treatment research.